Most up-to-date research on "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" to its huge collection of research reports.
Albany, NY -- (SBWIRE) -- 06/23/2014 -- Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
Browse Detail Report With TOC @ http://www.researchmoz.us/cebranopadol-neuropathic-pain-forecast-and-market-analysis-to-2022-report.html
Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Grnenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Grnenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain.
Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Cebranopadol for the top six countries from 2012 to 2022.
Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Browse Reports in Healthcare @ http://www.researchmoz.us/healthcare-market-reports-56.html
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Cebranopadol performance
Obtain sales forecast for Cebranopadol from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact: